Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: DNA methylation regulates sclerostin (SOST) expression in osteoarthritic chondrocytes by bone morphogenetic protein 2 (BMP-2) induced changes in Smads binding affinity to the CpG region of SOST promoter

Fig. 5

Occupancy of the SOST promoter by Smad1/5/8 by chromatin immunoprecipitation (ChIP) analysis. a Representative gel of Smad1/5/8 binding on the SOST promoter in cultured normal and osteoarthritis (OA) chondrocytes and densitometric analysis of the band intensity in cultured normal (n = 3) and OA chondrocytes (n = 3) (error bars = standard error, *p = 0.05 versus normal chondrocytes). b Representative gel of Smad1/5/8 binding on the SOST promoter in 5-AzadC- treated and untreated normal chondrocytes and densitometric analysis of the band intensity in three different samples (n = 3) (error bars = standard error, *p = 0.05 versus control) c Representative gel of Smad1/5/8 binding on the SOST promoter in bone morphogenic protein 2 (BMP-2)-treated and untreated normal and OA chondrocytes and densitometric analysis of the band intensity in normal (n = 3) and OA samples (n = 3) (error bars = standard error, *p = 0.05 versus control, NS = not significant). d Representative gel of Smad1/5/8 binding on the SOST promoter after BMP-2 treatment in cultured normal chondrocytes with or without 5-AzadC and densitometric analysis of the band intensity in three different samples (n = 3). (error bars = standard error, *p = 0.05 versus control and #p = 0.05 versus BMP-2 treatment). Input chromatin used as positive control and IgG as negative control. e Representative gel of Smad1/5/8 binding on the SOST promoter after 5-AzadC treatment in cultured normal chondrocytes with or without BMP-2 and densitometric analysis of the band intensity in three different samples (n = 3) (error bars = standard error, *p = 0.05 versus control, #p = 0.05 versus control and **p = 0.05 versus 5-AzadC treatment)

Back to article page